Non-DNA high-affinity cellular binding sites

Non-DNA high-affinity cellular binding sites is a pharmacological term used to describe the secondary binding characteristics of anthracenedione antineoplastic agents, most notably mitoxantrone (FDA, 2008). While these drugs primarily act by intercalating into DNA and inhibiting topoisomerase II, they also exhibit significant high-affinity binding to various non-DNA cellular components, including intracellular proteins and potentially mitochondrial or cytoskeletal structures (DrugBank, 2024). This non-specific binding is not attributed to a single molecular entity but rather a collection of sites that contribute to the drug's extensive tissue distribution and exceptionally long terminal half-life (PubChem, 2024). In a clinical context, these interactions are significant because they are associated with the drug's cumulative toxicities, such as dose-related cardiotoxicity, and its sustained therapeutic effects in treating conditions like multiple sclerosis (RxList, 2023). The sequestration of the drug at these sites leads to a slow release into the systemic circulation, which complicates the management of adverse effects and necessitates careful monitoring of cumulative dosage (StatPearls, 2023).

Other names

Non-DNA binding sitesHigh-affinity cellular binding sitesNon-specific cellular binding sites

These sites facilitate the intracellular sequestration and prolonged retention of anthracenedione drugs, contributing to their cytotoxic profile and long terminal half-life.